Introduction: Here, we demonstrate that baloxavir marboxil (hereafter referred to as baloxavir), a new selective inhibitor of influenza cap-dependent endonuclease, was effective in a highly immunocompromised patient with peramivir-resistant dual
E119D/
R292K NA mutated-influenza A/H3N2 after allo-HCT.